Skip to main content
. 2021 Apr 12;11:656078. doi: 10.3389/fonc.2021.656078

Figure 2.

Figure 2

Expression and diagnostic value of tRF-17-79MP9PP in clinical sample. (A) Scatter plot representation of tRF-17-79MP9PP levels in serum from healthy controls, benign breast diseases patients and breast cancer patients. (B) Expression of tRF-17-79MP9PP levels was quantified by qRT-PCR in tissues and NATs. (C) The correlation between 5’-tiRNAVal and tRF-17-79MP9PP in serum samples was analyzed with spearman correlation test. (D) The ROC-AUC of tRF-17-79MP9PP for differentiating all breast cancer patients from healthy control. (E, F) TNM stages I–II (E) and stages III–IV (F) in breast cancer from controls. (G, H) Non-Lymph node metastasis (G) and lymph node metastasis (H) in breast cancer from controls. U6 was used normalization. *p < 0.05; ** p < 0.01, *** p < 0.001 statistically significant. NATs, non-tumor adjacent tissues; ROC-AUC, Receiver Operating Characteristic-Area Under Curve; TNM, Tumor-Node-Metastasis. NS, no significance.